anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the field of biomedicine, in particular to a health-care product for increasing immunity and preventing and treating diabetes. The effective ingredients of Chinese medicinal herbs are extracted. The amino acid hypoglycemic capsule is the only road to scientifically develop traditional Chinese medicine and lead the traditional Chinese medicine to the world, and is required by people's health guaranteeing and preventive medicine. Diabetes is a medical difficulty which is not conquered in the world. Effects are achieved through years of researches. The hypoglycemic capsule contains no Western medicine ingredients, has no side effect and has the effects of preventing and treating diabetes, which brings a piece of good news for more and more patients with diabetes. The amino acid hypoglycemic capsule is based on the theory of the traditional Chinese medical science and completes the balance of yin and yang in the body. The mechanism of balancing and mutually complementing yin and yang is achieved by producing yang at extreme yin and producing yin at extreme yang and mutually converting. The amino acid hypoglycemic capsule is developed with the aim of exploring nutrition, health care, and preventing diseases and with the emphasis on nutrition by a scientific method. The amino acid hypoglycemic capsule has the effects of reinforcing primordial qi and strengthening the body resistance to eliminate pathogenic factors. The amino acid hypoglycemic capsule has the functions for increasing immunity and regulating endocrine metabolism so as to achieve the effects which can not be realized by Western medicine.
For patients in the successful MT only group, the choice of MT strategy will be made by the qualified neurointerventionalist, including stent retriever, aspiration and a combination technology. Patients who underwent more than 3 thrombectomy procedures were excluded from the study. Rescue therapy was performed at the discretion of the neurointerventionalist in case of the grade of stenosis at the occlusion site was presented to be more than 70% after MT.
We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) \< perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
Participants with primary CAD who had a recent history of transfusion (defined as at least 1 transfusion during the last 6 months prior to screening) received an intravenous (IV) infusion of BIVV009 6.5 grams (g) (if body weight was less than \[\<\] 75 kilograms \[kg\]) or BIVV009 7.5 g (if body weight was greater than or equal to \[\>=\] 75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) could continue to receive BIVV009 in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks. All participants who completed Part A elected to continue in Part B.
All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
This is a prospective single-arm phase II study designed to study the efficacy of high dose rate (HDR) brachytherapy with CT-imaging, single-fraction intraoperative radiation therapy (IORT). The study will accrue patients with early-stage breast cancer who will be treated with breast-conserving surgery (BCS). The main clinical eligibility criterion is based on suitability for accelerated partial breast irradiation. Patients may be eligible prior to receiving BCS or within 30 days of receiving BCS. Eligible patients that will undergo BCS will receive surgery according to the standard clinical practice in the Brachytherapy Suite in the Emily Couric Clinical Cancer Center. Patients that have already undergone BCS must meet all other eligibility criteria and are able to be treated with IORT within 30 days of their breast surgery. Eligible subjects will undergo a lumpectomy or re-excision lumpectomy according the standard clinical practice. Immediately following lumpectomy, the breast HDR brachytherapy applicator will be placed and CT imaging will be performed for treatment planning. After HDR brachytherapy is delivered, the applicator will be removed, and the breast surgeon will complete the skin closure. Although the ultimate goal of the study is to determine 5-year ipsilateral breast tumor recurrence (IBTR), all efforts will be made to follow the patients until death.
PROBLEM TO BE SOLVED: To provide an emulsification stabilizer comprising an oil-in-water compsn. which not only forms an extremely stable emulsified state when added to a well-known emulsifier but can form a good emulsified state even when the stabilizer is used in a single state, and which shows high safeness. SOLUTION: This emulsification stabilizer consists of an esterified product of glycerine polymer and one or more kinds of fatty acids selected from 8 to 18C, preferably 16 to 18C straight-chain fatty acids, unsatd. fatty acids and branched fatty acids or 9 to 20C fatty satd. dibasic acids satisfying glycerine polymer : fatty satd. dibasic acids = 1:(0.3 to 0.5) molar ratio. The emulsification stabilizer consists of a partially esterified product in which 50 to 75%, preferably 55 to 75% of hydroxyl groups in the glycerine polymer remain.
OBJECTIVE: The aim of this study was to demonstrate the establishment of adrenal sparing in intrauterine growth restricted (IUGR) human fetuses. IUGR fetuses are a subgroup of small for gestational age (SGA) fetuses that are unable to reach their own growth potential because of chronic hypoxia and undernutrition. We hypothesized that in IUGR fetuses the adrenal gland is relatively larger and secretion of noradrenaline (NA), adrenaline (A), and cortisol is increased.
STUDY DESIGN: This is a prospective observational study including 65 singleton pregnancies (42 IUGR and 23 controls). Using two-dimensional ultrasound, we measured fetal adrenal diameters and adrenal/abdominal circumference (AD/AC) ratio between 25 and 37 weeks. We considered only one measurement per fetus. In 21 pregnancies we also measured NA, A, and cortisol levels in arterial and venous fetal cord blood collected at the time of delivery.
RESULTS: The AD/AC ratio was significantly higher in IUGR fetuses than in controls. Cord NA and A levels were significantly higher in IUGR fetuses than in controls. An increase in cortisol secretion in IUGR fetuses was observed but the difference was not statistically significant.
CONCLUSIONS: Adrenal sparing correlates with a relative increase in adrenal measurements and function.
Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
In the first live-bearing mammals, pregnancy was likely short and ended with a brief period of inflammatory maternal-fetal interaction. This mode of reproduction has been retained in many marsupials. While inflammation is key to successful implantation in eutherians, a key innovation in eutherians is the ability to switch off this inflammation after it has been initiated. This extended period, in which inflammation is suppressed, likely allowed for an extended period of placentation. Extended placentation has evolved independently in one lineage of marsupials, the macropodids (wallabies and kangaroos), with placentation lasting beyond the 2 to 4 d seen in other marsupial taxa, which allows us to investigate the role of inflammation response after attachment in the extension of placentation in mammals. By comparing gene expression changes at attachment in three marsupial species, the tammar wallaby, opossum, and fat-tailed dunnart, we show that inflammatory attachment is an ancestral feature of marsupial implantation. In contrast to eutherians, where attachment-related (quasi-) inflammatory reaction is even involved in epitheliochorial placentation (e.g., pig), this study found no evidence of a distinct attachment-related reaction in wallabies. Instead, only a small number of inflammatory genes are expressed at distinct points of gestation, including IL6 before attachment, LIF throughout placentation, and prostaglandins before birth. During parturition, a more distinct inflammatory reaction is detectable, likely involved in precipitating the parturition cascade similar to eutherians. We suggest that in wallaby, extended gestation became possible by avoiding an inflammatory attachment reaction, which is a different strategy than seen in eutherians.
Previous studies suggest a role for inflammation in hepatocarcinogenesis. However, no study has comprehensively evaluated associations between circulating inflammatory proteins and risk of hepatocellular carcinoma (HCC) among the general population. We conducted a nested case-control study in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) with 56 pairs of incident HCC cases and controls. External validation was performed in the UK Biobank (34 HCC cases and 48,471 non-HCC controls). Inflammatory protein levels were measured in pre-diagnostic plasma using the Olink® Inflammation Panel. We used conditional logistic regression to calculate multivariable odds ratios (ORs) with 95% confidence intervals (CIs) for associations between a 1-standard deviation (SD) increase in biomarker levels and HCC risk, considering a statistically significant threshold of false discovery rate (FDR)-adjusted p < .05. In the NHS/HPFS, among 70 analyzed proteins with call rates >80%, 15 proteins had significant associations with HCC risk (pFDR < .05). Two proteins (stem cell factor, OR per SD = 0.31, 95% CI = 0.16-0.58; tumor necrosis factor superfamily member 12, OR per SD = 0.51, 95% CI = 0.31-0.85) were inversely associated whereas 13 proteins were positively associated with risk of HCC; positive ORs per SD ranged from 1.73 for interleukin (IL)-10 to 2.35 for C-C motif chemokine-19. A total of 11 proteins were further replicated in the UK Biobank. Seven of the eight selected positively associated proteins also showed positive associations with HCC risk by enzyme-linked immunosorbent assay, with ORs ranging from 1.56 for IL-10 to 2.72 for hepatocyte growth factor. More studies are warranted to further investigate the roles of these observed inflammatory proteins in HCC etiology, early detection, risk stratification, and disease treatment.
Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
The acupuncture group and the sham-controlled group will receive three therapeutic sessions each week for four weeks, and another two sessions each week for four weeks (a total of 20 sessions at eight weeks). Each group will be followed-up for four weeks, to evaluate the persistent efficacy of acupuncture.The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3 mm×30 mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
Group A will perform aerobic and resistance exercises at a moderate level. Brisk Walk on treadmill 5 days/week with 40-70% of Vo2max (maximal aerobic capacity) 150 min/week 50-55% humidity and a room temperature of 24-25 °C will maintain. The subject will wear insole proper fitted shoes. Aerobic exercise will be conducted for a total of 30 minutes per session for 5 days for 12 weeks. This protocol will be followed by a 10-minute warm-up and cool-down. Followed by 10-15 minutes of resistance-based exercises at a moderate intensity of three sets with 15 repetitions of upper and lower limbs respectively i.e. Dumbbell biceps curl, Standing dumbbell triceps extension, Dumbbell stiff-legged deadlifts and Dumbbell squats Resistance loads will be 40-50% of one repetition maximum. The resting interval between resistance training sets will be \< 1 min.
PURPOSE:To enable establishment of immunochemical assay for specifically measuring human lymphotoxin with high sensitivity by using a human lymphotoxin neutralized monoclonal antibody produced by an antibody-producing hybridoma. CONSTITUTION:A DNA capable of coding an N-terminal-deficient human lymphotoxin (hereinafter abbreviated to LT) is prepared. The resultant DNA is then inserted into the 3'-terminal of a promoter region functioning in a host, such as Escherichia coli, to construct a recombinant DNA. The obtained transformant is subsequently cultured in a culture medium, such as L-broth. After the culture, microbial cells are collected and broken to provide an N- terminal-deficient LT. The resultant LT is then inoculated into a mouse to promote production of an anti-human LT antibody. The spleen or lymph node is collected 3-5 days after the final immunization and antibody-producing cells contained therein are fused to myelomatous cells, such as P3U1, and afford a human LT antibody-producing hybridoma. Thereby a sandwiching (SW) method is used for a human LT immunochemical assay.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used for treating patients with metabolic syndrome. That is ensured by introducing Metformin 500 mg twice a day, Atorvastatin 10 mg in the evening, Lysinopryl 5 mg 1-2 times a day. It is combined with intravenous laser blood irradiation (ILBI) at wave length 0.405 mcm, output power at trunk light guide end 1–1.5 mWt for 15 minutes in continuous illumination mode. ILBI is differentiated depending on the duration of the disease, level of lipid metabolism, level of leptin and adiponectin concentration in blood serum. If disease duration is less than 3 years, with LDL cholesterol less than 3.5±0.59 mmol/l, HDL cholesterol more than 1.2±0.04 mmol/l, TG less than 1.62±0.16 mmol/l, leptin level equal to or less than 20±0.42 pg/ml, adiponectin level equal to or less than 6±0.45 pg/ml is followed by 7 daily procedures of ILBI. If the disease lasts more than 3 years, with a LDL cholesterol level greater than 3.5±0.59 mmol/l, a cholesterol HDL less than 1.2±0.04 mmol/l, a TG more than 1.62±0.16 mmol/l, leptin level more than 20±0.42 pg/ml, level of adiponectin more than 6±0.45 pg/ml 10 daily procedures are performed.EFFECT: such implementation of the method provides more effective drug-induced treatment, reduced clinical manifestations of metabolic syndrome, reduced drug load on the patient, normalized carbohydrate metabolism, leptin, adiponectin and cytokines.1 cl, 8 tbl, 2 ex
The study has one group/cohort, which will include up to 154 people. The study team will conduct one round of semi-structured interviews with up to 42 administrators or other staff at the centralized intake system organization(s), 28 home visiting program directors and other staff responsible for overseeing outreach and enrollment, 42 home visitors and other staff responsible for conducting outreach and enrollment, and 42 families who were referred to home visiting through the selected centralized intake systems. All respondents will also complete a form to provide information about their demographic characteristics.
Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
PURPOSE:To provide a new compound having brain function-improving activity, thus useful for the prevention or curing of Alzheimertype dementia. CONSTITUTION:The objective compound of formula I [A is CH, N or N oxide; R1 is nitro or amino; R2 is H, lower alkyl or acyl; R3 is formula II ((m) is 0 or 1; (n) is 0-3; R4 and R5 are each H or lower alkyl; R6 and R7 are each H, lower alkyl, etc.; dotted line is a ring present as the case may be], e.g. 4-(1-azabicyclo[3,3,0]octan-5-yl)methylamino-3-nitroquinoline. The compound of the formula I can be obtained by reaction between a compound of formula III (X is halogen or alkoxy) and a compound of formula IV in a solvent (e.g. DMF) or in the absence of a solvent at 0-180 deg.C. The compound of the formula I is low toxic and excellent in safety, and can be administered for a long period of time.
A novel structure of sense and antisense oligonucleotides, namely closed oligonucleotides, is described. Closed oligonucleotides, advantageously circular oligonucleotides, for example, may be used pharmacologically as sense or antisense molecules. Methods for chemically and/or biologically obtaining such molecules are also described. The therapeutic use of the oligonucleotides as sense or antisense agents poses several problems, including the problem of molecule stability. Antisense oligonucleotides undergo nucleolytic degradation and are mainly sensitive to exonucleases. The closed antisense olignucleotides of the invention are molecules with no free ends and are therefore more resistant to exonuclease attacks. The closed oligonucleotides can act as antisense factors and last longer than the corresponding linear oligonucleotides. Furthermore, closed antisense oligonucleotides which are circular or have a complex secondary structure allow the secondary and tertiary structures of target messenger RNAs to be taken into account. For instance, such antisense oligonucleotides may be multifunctional and interact with several regions which are not adjacent to the target RNA. Moreover, closed oligonucleotides may be used according to a 'sense'-type strategy to interact specifically with protein factors having an affinity for certain RNA or DNA sequences or structures. Generally speaking, the closed and, in particular, circular oligonucleotides described here may be used in all cases where it is preferable to have available an oligonucleotide having increased resistance to exonucleases compared with an olignucleotide which has the same sequence but is linear.
Sickle cell anemia is a serious life-limiting and potentially life-threatening condition that causes disruption in the lifestyle of the affected child. Pain is a common and severe symptom of sickle cell disease (SCD) and is the major reason that patients seek health care services. Some researchers supported the fact that an important impairment in balance control and muscle strength in children with sickle cell disease due to pressure pain tolerance problems and other factors. Significant decrease in exercise capacity was seen in sickle cell anemic children. The altered muscle function and balance observed in SCD children may collectively be the result of pressure pain tolerance impairment. As your physical fitness improves, your body becomes more efficient at getting oxygen into the bloodstream and transporting it to the working muscles. Along this observational correlational study design; Eighty children from both sexes will be participated in this study. Forty normal healthy children will be selected from primary governmental schools at Alexandria governorate and forty children with sickle cell anemia will be selected from Alexandria University Students Hospitals For evaluation of muscle strength hand held dynamometer (Lafayette) is one of the best methods to detect the muscle strength. It is an ergonomic hand-held device for objectively quantifying muscle strength
OBJECTIVES: Fungal bloodstream infection (fBSI) following pediatric liver transplantation presents a significant challenge; however, there remains a paucity of guidance regarding antifungal prophylaxis in this population. This study aimed to evaluate the effectiveness of universal antifungal prophylaxis and propose a desirable strategy.
METHODS: We enrolled 604 pediatric patients who underwent liver transplantation between 2020 and 2023, including 242 patients with empirical prophylaxis and 362 patients with universal prophylaxis. Univariate and multivariate logistic regression analyses were performed to identify independent factors for fBSI.
RESULTS: Eight (2.2%) pediatric recipients in the universal prophylaxis group and 13 (5.4%) in the empirical group developed fBSI (P = 0.038). Universal prophylaxis was a protective factor (P = 0.044), while high-volume intraoperative plasma transfusion and deceased donor liver transplantation were independent risk factors for fBSI (P = 0.035 and 0.008, respectively). Universal antifungal strategy showed an increased overall survival trend after liver transplantation although without significant statistical difference (P = 0.217). Patients with fBSI had poorer survival than those without fBSI (P <0.001).
CONCLUSIONS: Universal prophylaxis strategy for fBSI in pediatrics after liver transplantation is desirable as it could markedly decrease the occurrence of fBSI. Pediatric patients with deceased donors and high-volume intraoperative transfusion should be paid more attention to preventing fBSI.
Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
This will be a prospective study undertaken at the Renal Transplant Unit of Hospital of Clinics of Porto Alegre. In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities. The presence of donor-specific antibodies and graft-damaging infectious agents will also be searched in the peripheral blood at the time of biopsy.One hundred patients will be randomized to a protocol biopsy and noninvasive assessment or only for noninvasive assessment. The hypothesis of the study is that biopsies will lead to treatments that may allow better outcomes of renal transplants, related to lowering the progression of subclinical aggressions, avoiding or delaying graft loss and preserving or decreasing the rate of loss of the glomerular filtration rate. Therefore, this strategy has the possibility of reaching clinical practice routine and thus contribute positively to the management of renal transplant patients.